Here is a stock with buy rank and strong momentum characteristics for investors to consider today, October 10th:
Spero Therapeutics SPRO: This multi-asset, clinical-stage biopharmaceutical company which is focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, has a Zacks Rank #1 (Strong Buy), and witnessed the Zacks Consensus Estimate for its current year earnings increasing 44.8% over the last 60 days.
Spero Therapeutics, Inc. Price and Consensus
Spero Therapeutics, Inc. price-consensus-chart | Spero Therapeutics, Inc. Quote
Spero Therapeutics' shares gained 293.3% over the last six months compared with the S&P 500’s gain of 25.6%. The company possesses a Momentum Score of B.
Spero Therapeutics, Inc. Price
Spero Therapeutics, Inc. price | Spero Therapeutics, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Spero Therapeutics, Inc. (SPRO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research